Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial

What Was Tested

This randomized controlled trial paper looks at Exenatide.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults.

Thirty patients with type 2 diabetes were randomized to weekly EXE and daily DAPA (n = 16) or weekly PLAC and daily DAPA (n = 14).

The primary endpoint, HCL levels, were measured at baseline and after 24 weeks of treatment using magnetic resonance spectroscopy.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and pilot.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Exenatide.

The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger Exenatide study would be practical.

The methods mention a period of 24 weeks.

Between-group effects were analysed using general linear models, adjusted for baseline outcome variables, age, sex and BMI.

Within-group differences were assessed using a paired t-test.

What Was Measured

Topics PubMed links to this paper include Benzhydryl Compounds, Blood Glucose, Carcinoma, Hepatocellular, Diabetes Mellitus, Type 2, Exenatide, Glucosides and Glycated Hemoglobin.

Author keywords: CVD, GLP-1 receptor agonist, NAFLD, SGLT2 inhibitor, ectopic lipids and glycaemic control.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide over 24 weeks.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Exenatide compound page.